Holen Sie sich die Stockscreener-App
76.87
0.93%
-0.72
Schlusskurs vom Vortag:
$77.59
Offen:
$77.31
24-Stunden-Volumen:
1.24M
Relative Volume:
0.91
Marktkapitalisierung:
$9.05B
Einnahmen:
$12.50B
Nettoeinkommen (Verlust:
$314.00M
KGV:
31.50
EPS:
2.44
Netto-Cashflow:
$421.00M
1W Leistung:
-1.11%
1M Leistung:
+0.97%
6M Leistung:
+7.57%
1J Leistung:
+0.23%
1-Tages-Spanne:
$76.36
$77.42
1-Wochen-Bereich:
$76.36
$79.44
52-Wochen-Spanne:
$60.56
$82.49
Henry Schein Inc Stock (HSIC) Company Profile
Firmenname
Henry Schein Inc
Sektor
Branche
Telefon
(631) 843-5500
Adresse
135 DURYEA RD, MELVILLE, NY
Vergleichen Sie HSIC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
76.87 | 9.13B | 12.50B | 314.00M | 421.00M | 2.44 |
|
MCK
Mckesson Corporation
|
834.18 | 102.03B | 387.09B | 4.23B | 6.01B | 32.12 |
|
COR
Cencora Inc
|
356.14 | 69.16B | 321.33B | 1.57B | 3.21B | 7.9518 |
|
CAH
Cardinal Health Inc
|
214.04 | 50.12B | 234.31B | 1.61B | 4.45B | 6.6243 |
|
AHG
Akso Health Group Adr
|
1.43 | 774.37M | 2.22M | -5.63M | -1.68M | -0.24 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-02-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-01-06 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-07-22 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-11-10 | Hochstufung | Stifel | Hold → Buy |
| 2022-08-08 | Hochstufung | UBS | Sell → Neutral |
| 2022-07-21 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-01-31 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-01-07 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-10-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-02-08 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-01-04 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-11-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-04-07 | Hochstufung | Goldman | Neutral → Buy |
| 2020-04-02 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-09 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2020-01-02 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2019-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-05-30 | Eingeleitet | Wolfe Research | Underperform |
| 2019-05-15 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-01-17 | Eingeleitet | UBS | Sell |
| 2019-01-03 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2019-01-02 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2018-11-08 | Bestätigt | Barrington Research | Outperform |
| 2018-10-25 | Herabstufung | Edward Jones | Hold → Sell |
| 2018-10-19 | Fortgesetzt | Goldman | Neutral |
| 2018-10-04 | Bestätigt | Robert W. Baird | Outperform |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-04-24 | Herabstufung | Goldman | Buy → Neutral |
| 2018-04-04 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
Alle ansehen
Henry Schein Inc Aktie (HSIC) Neueste Nachrichten
Briefly: NCPA, Henry Schein Announce New Executive Leaders - HME Business
Analyst Downgrade: Will Henry Schein Inc. benefit from green energy policiesEarnings Beat & Expert Approved Trade Ideas - baoquankhu1.vn
Henry Schein Schedules Q4 2025 Earnings Call - Dentistry Today
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET - BioSpace
How Investors Are Reacting To Henry Schein (HSIC) New CEO Pick And Exclusive CitoCBC Deal - simplywall.st
Henry Schein Shares Consolidate as Technical and Fundamental Catalysts Align - AD HOC NEWS
Henry Schein Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Dilation Capital Management LP Invests $5.11 Million in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein Names Frederick M. Lowery as Chief Executive Officer - Zenopa
Henry Schein, Inc. (NASDAQ:HSIC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Henry Schein Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途资讯
The Truth About Henry Schein Inc: Why Wall Street Is Watching (But TikTok Barely Cares…Yet) - AD HOC NEWS
Mizuho Adjusts Price Target on Henry Schein to $81 From $74, Maintains Neutral Rating - marketscreener.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Here's What to Expect From Henry Schein's Next Earnings Report - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX) - The Globe and Mail
Mixed Strategic Drivers Led Upslope Capital Management to Pick Henry Schein (HSIC) - Insider Monkey
Tetratherix executes global distribution & supply agreement with Henry Schein - marketscreener.com
Tetratherix Executes Global Distribution & Supply Agreement With Henry Schein - TradingView — Track All Markets
Newly listed biotech Tetratherix secures global distribution deal with US giant Henry Schein - Business News Australia
Australia's Tetratherix hits four-week high on supply deal with Henry Schein - TradingView — Track All Markets
Henry Schein (NASDAQ:HSIC) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Henry Schein names new CEO - DrBicuspid.com
Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement - Yahoo Finance
Henry Schein inks exclusive U.S. distribution deal for CLIA-waived CBC system - Medical Economics
Henry Schein enters distribution agreement for CytoChip's CLIA-waived hematology analyzer - marketscreener.com
Henry Schein Enters Distribution Agreement For CytoChip’S CLIA-Waived Hematology Analyzer - TradingView — Track All Markets
Henry Schein Agrees to Distribute CytoChip's CitoCBC system - marketscreener.com
Henry Schein (HSIC) Partners with CytoChip for Exclusive Distrib - GuruFocus
Henry Schein to distribute FDA-cleared blood test system nationwide - Investing.com
Henry Schein to distribute FDA-cleared blood test system nationwide By Investing.com - Investing.com South Africa
Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer - joplinglobe.com
3 Reasons to Sell HSIC and 1 Stock to Buy Instead - Yahoo Finance
Henry Schein names a new CEO - Digital Commerce 360
JPM26: Henry Schein focuses on high-margin, high-growth business as new CEO announced - Yahoo Finance
Henry Schein extends private placement facilities to 2028 - MSN
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term - sharewise.com
Henry Schein Seeks M&A Opportunities - marketscreener.com
Henry Schein Taps Former Thermo Fisher Exec as New CEO - Modern Distribution Management
Will Henry Schein’s (HSIC) New External CEO and Governance Shift Reframe Its Leadership Narrative? - simplywall.st
Henry Schein Names Thermo Fisher Exec Fred Lowery as CEO - Medical Product Outsourcing
Frederick Lowery named new CEO of Henry Schein, effective March 2026 - Investing.com Nigeria
Henry Schein appoints Frederick Lowery as CEO - MSN
Leadership transition at Henry Schein: Frederick M. Lowery to take over as CEO - Dental Tribune US
Henry Schein names Frederick M. Lowery as new CEO - newsday.com
Henry Schein Appoints Frederick M Lowery as New CEO - Orthodontic Products
Henry Schein, Inc. Announces Management Changes - marketscreener.com
Henry Schein, Inc. Appoints Frederick M. Lowery as Chief Executive Officer, Effective March 2, 2026 - marketscreener.com
Henry Schein names Frederick Lowery as new CEO - libn.com
Henry Schein (HSIC) Appoints Frederick Lowery as New CEO - GuruFocus
Finanzdaten der Henry Schein Inc-Aktie (HSIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.42%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):